Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

易普利姆玛 无容量 医学 危险系数 黑色素瘤 内科学 安慰剂 肿瘤科 癌症 免疫疗法 癌症研究 置信区间 替代医学 病理
作者
James Larkin,Vanna Chiarion‐Sileni,Rene C. Gonzalez,Jean‐Jacques Grob,Piotr Lukasz Rutkowski,Christopher D. Lao,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,David Hogg,Andrew Hill,Iván Márquez‐Rodas,John B.A.G. Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,Matteo Salvatore Carlino
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:381 (16): 1535-1546 被引量:3717
标识
DOI:10.1056/nejmoa1910836
摘要

BACKGROUNDNivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma.We now report 5-year outcomes in the trial. METHODSWe randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo.The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. RESULTSAt a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63).Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group.No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone.No new late toxic effects were noted. CONCLUSIONSAmong patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.(Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.govnumber, NCT01844505.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ditf完成签到,获得积分10
刚刚
刚刚
1秒前
1秒前
2秒前
NexusExplorer的应助被wiiiiwi采纳,获得10
3秒前
lhk关闭了lhk的文献求助
3秒前
情怀的应助被igiss采纳,获得10
3秒前
3秒前
兽先生完成签到 ,获得积分10
5秒前
fvxbgv完成签到,获得积分10
5秒前
勤恳兔子的应助被qrj采纳,获得10
5秒前
科研通AI65的应助被小王小王采纳,获得10
5秒前
5秒前
盒子发布了新的文献求助30
5秒前
6秒前
6秒前
珊珊完成签到,获得积分10
7秒前
Owen的应助被细心的凡蕾采纳,获得10
7秒前
zz完成签到,获得积分20
7秒前
7秒前
JamesPei的应助被元宵采纳,获得10
8秒前
Canyon老师发布了新的文献求助10
8秒前
26发布了新的文献求助10
9秒前
10秒前
10秒前
11秒前
Joyhold发布了新的文献求助10
12秒前
小巧秋天完成签到,获得积分20
12秒前
fafamimireredo完成签到,获得积分10
12秒前
13秒前
代曼发布了新的文献求助10
13秒前
科目三的应助被肥猫采纳,获得10
13秒前
华仔的应助被才思敏捷的橙子采纳,获得10
14秒前
小巧秋天发布了新的文献求助10
14秒前
JamesPei的应助被鑫妍妍采纳,获得10
14秒前
万能图书馆的应助被LingYi采纳,获得10
15秒前
Joyhold发布了新的文献求助10
18秒前
ZBYN完成签到,获得积分10
19秒前
啊啊啊啊完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067